silodrostat is a potent inhibitor of human 11β-hydroxylase and aldosterone synthase with IC₅₀ values of 2.5 and 0.7 nM, respectively.

>98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

LCI-699；LCI699

DMSO : 250 mg/mL (1100.16 mM; Need ultrasonic)
Ethanol : 100 mg/mL (440.06 mM; Need ultrasonic)

11β-hydroxylase

LCI699 also inhibits aldosterone synthase (CYP11B2) other than CYP11B1.

LCI699 is a potent inhibitor of 11β-hydroxylase (CYP11B1), the enzyme that catalyzes the final step of cortisol synthesis, and has a half-life of ∼4 hours. It decreases blood pressure (BP) in patients with essential hypertension and primary aldosteronism. Treatment with LCI699 is well tolerated, it is demonstrated efficacy with a satisfactory safety and tolerability profile in the proof-of-concept study in Cushing’s disease. The administration of LCI699, up to 1.0 mg BID, effectively and safely inhibits aldosterone synthase in patients with primary aldosteronism.